by Jason Heaviland | Jun 12, 2026
ChatGJP: Discovery vs Targeted Exposomics Explained Should you use discovery exposomics or targeted exposomics? In this episode of ChatGJP, Panome Bio CEO Ed Weinstein explains the strengths of each approach and how they work together to provide a comprehensive...
by Jason Heaviland | Jun 2, 2026
ChatGJP: Exposomics, PFAS, and Clinical Trial Implications In this episode of ChatGJP, Panome Bio President and Co-Founder Tom Cohen explores the growing field of exposomics and its role in understanding how environmental exposures influence human health and disease....
by Jason Heaviland | Apr 14, 2026 | Uncategorized
In exposomics, there are two fundamentally different ways to explore the chemical world influencing human health and choosing the right one can make or break your study. Think of it like this: Are you searching for something specific or are you trying to discover what...
by Jason Heaviland | Mar 25, 2026
Pinpointing the Pervasive: Exposomics Analysis of Alzheimer’s Disease This poster presents a comprehensive exposomics analysis of Alzheimer’s disease, leveraging both targeted and discovery workflows to characterize environmental exposures and their biological impact....
by Jason Heaviland | Mar 2, 2026
Exposomics Measuring Chemical Drivers of Human Disease Panome Bio’s Exposomics platform enables comprehensive measurement of chemical exposures that drive human disease. Using integrated discovery (32,000+ compounds) and targeted profiling (235 priority chemicals), we...
